Xencor (XNCR) Receivables (2013 - 2026)
Xencor (XNCR) posted quarterly Receivables of $12.0 million for Q1 2026, down 68.24% year-over-year from $37.8 million in Q1 2025, and down 59.04% quarter-over-quarter from $29.3 million in Q4 2025.
Analysis
Xencor (XNCR) Receivables (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Receivables for 14 consecutive years, with $12.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 68.24% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $12.0 million (down 68.24% YoY), while the FY2025 annual figure was $29.3 million, down 55.97% from the prior year.
- Receivables fell to $12.0 million in Q1 2026 per XNCR's latest filing, from $29.3 million in the prior quarter.
- Across five years, Receivables topped out at $93.2 million in Q1 2022 and bottomed at $2.2 million in Q3 2023.
- Historically, Receivables has averaged $34.7 million across 5 years, with a median of $29.3 million in 2025.
- Annual changes were most pronounced in 2022 — Receivables soared 5328.4% — and 2023, when it tumbled 95.1%.
- Xencor's Receivables stood at $30.3 million in 2022, then declined by 14.05% to $26.0 million in 2023, then surged by 155.57% to $66.5 million in 2024, then slumped by 55.97% to $29.3 million in 2025, then plunged by 59.04% to $12.0 million in 2026.
- Business Quant data shows XNCR's Receivables at $12.0 million in Q1 2026, $29.3 million in Q4 2025, and $21.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 42.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.23 Mn |
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | 29.30 Mn |
| Sep 30, 2025 | 21.81 Mn |
| Jun 30, 2025 | 47.55 Mn |
| Mar 31, 2025 | 37.79 Mn |
| Dec 31, 2024 | 66.55 Mn |
| Sep 30, 2024 | 25.87 Mn |
| Jun 30, 2024 | 35.92 Mn |
| Mar 31, 2024 | 22.18 Mn |
| Dec 31, 2023 | 26.04 Mn |
| Sep 30, 2023 | 55.00 Mn |
| Jun 30, 2023 | 20.02 Mn |
| Mar 31, 2023 | 19.86 Mn |
| Dec 31, 2022 | 30.30 Mn |
| Sep 30, 2022 | 44.88 Mn |
| Jun 30, 2022 | 54.28 Mn |
| Mar 31, 2022 | 93.20 Mn |
| Dec 31, 2021 | 67.18 Mn |
| Sep 30, 2021 | 20.55 Mn |